No Data
No Data
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Beam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy Rating
Beam Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 4:30 PM ET
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
Beam Therapeutics Advances Base Editing Portfolio